Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

CDK4/6 inhibitor plus endocrine therapy is an active treatment option for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer compared with chemotherapy ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

These data contribute to the ongoing debate about the optimal sequencing of therapies for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, and might suggest that ...

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

The effects of mTOR inhibition on CDT have been well-studied in various cancer models, and these studies have revealed that alterations to mTOR signaling affect the translation of specific subsets of ...

The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

引言激素受体阳性（HR+）/人表皮生长因子受体 2 阴性（HER2-）乳腺癌是最常见的乳腺癌亚型，约占所有乳腺癌的 70%。近年来，细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂联合内分泌治疗已成为 HR+/HER2- 晚期乳腺癌的一线标准治疗 ...